Advertisement

Product › Details
AI-based drug discovery / AI-based drug development
![]() |
Next higher product group | drug discovery |
Atomwise, Inc.. (9/11/19). "Press Release: Atomwise Announces Largest China-US Collaboration for AI Drug Discovery". San Francisco, CA.
Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules
Atomwise Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discovery, today announced a collaboration with Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.
“There is exciting science happening throughout Asia, and enormous potential for leadership in innovative drug discovery,” said Dr. Abraham Heifets, CEO of Atomwise. “I am delighted to announce that Hansoh Pharma is our first partner in Asia. Hansoh Pharma is committed to innovation and shares our mission for global impact on patient health,” he added.
Scientific teams from Atomwise and Hansoh Pharma will collaborate closely on the programs. The combination of Atomwise’s AI technology and medicinal chemistry and protein structure expertise, and Hansoh Pharma’s fully integrated research and development, manufacturing and commercial capabilities has the potential to dramatically increase success and compress timelines for drug discovery and clinical development.
Under the terms of the collaboration, Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the collaboration. Based on historical average revenues for small molecule drugs, the total potential value of the deal to Atomwise with success in all projects could reach US$1.5 billion.
About Atomwise
Atomwise Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as over a hundred universities and hospitals in 19 countries. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology. Learn more at atomwise.com or follow @AtomwiseInc.
Media Contact
Sara Dunn
[email protected]
Record changed: 2025-01-13 |
Advertisement

More documents for AI-based drug discovery / AI-based drug development
- [1] BenevolentAI Ltd.. (12/11/24). "Press Release: BenevolentAI Unveils Major Strategic Overhaul with Return to Original Mission". London....
- [2] Relation Therapeutics Ltd.. (12/10/24). "Press Release: Relation Announces Two Strategic Collaborations with GSK to Advance Therapeutics for Fibrotic Diseases and Osteoarthritis". London....
- [3] Aqemia SAS. (12/10/24). "Press Release: Aqemia Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK". Paris & London....
- [4] BenevolentAI Ltd.. (10/17/24). "Press Release: BenevolentAI Appoints Kenneth Mulvany as Executive Chairman". London....
- [5] Shift Bioscience Ltd.. (10/15/24). "Press Release: Shift Bioscience Raises $16M to Advance Cell Simulation AI Platform". Cambridge....
- [6] Antiverse Ltd.. (10/15/24). "Press Release: Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform". Cardiff....
- [7] Closed Loop Medicine Ltd.. (9/11/24). "Press Release: Closed Loop Medicine Appoints Luba Greenwood as Chair of the Board of Directors". London....
- [8] Exscientia plc. (8/28/24). "Press Release: Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference". Oxford....
- [9] Recursion Pharmaceuticals, Inc.. (8/8/24). "Press Release: Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities". Salt Lake City, UT & Oxford....
- [10] Iambic Therapeutics Inc.. (6/18/24). "Press Release: Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top